$7.36
−1.60%Price chart
Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15
Key dataSep 15, 2026
Open$7.40
From 52W high−26.55%
Volume590607.00
Market cap$5.01B
P/E (TTM)9.5x
P/S (TTM)0.6x
Div yield1.28%
Key dataSep 15, 2026
Open
$7.40
From 52W high
−26.55%
Volume
590607.00
Market cap
$5.01B
ValuationView details →
P/E (Fwd)
10.5x
EV/EBITDA
8.4x
P/E (TTM)
9.5x
RSI (14)
38.2
MomentumView details →
1D Return
−1.60%
YTD Return
−20.16%
SummaryUpdated Jun 1, 2026
Grifols, S.A. (NASDAQ:GRFS) is a Spanish multinational pharmaceutical and chemical company founded in 1940 and headquartered in Barcelona, Spain. The company went public on NASDAQ in 2011 and has grown to become one of the world's largest producers of plasma-derived medicines. Grifols operates through multiple divisions including Bioscience, Hospital, Diagnostic, and Bio Supplies, serving healthcare providers globally with products used to treat chronic, rare, and life-threatening diseases. The company has undergone significant operational restructuring in recent years, including leadership changes with Nacho Abia becoming CEO in 2024, as it works to improve financial performance and reduce leverage following a period of rapid expansion.
Similar companies
Latest newsMore news →
Grifols replaced Barzin Bahardoust as sole director of Grifols Canada Plasma Corporation with three Grifols executives based in Canada, the United States and Spain on Sept. 1, 2026.1d agoGrifols temporarily paused plasma collection at all its donation centres across Canada.33d agoGrifols announced the completion of the clinical portion of its Phase 3 SPARTA study evaluating Prolastin-C in patients with emphysema due to alpha-1 antitrypsin deficiency.37d ago